Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
My Best Biotech Stock for 2021
06:56am, Friday, 08'th Jan 2021
Here's why the biggest biotech IPO of 2019 outshines all its peers.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 06'th Jan 2021
PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on January 4, 2
3 Biotech Stocks That Could Double Your Money in 2021
06:23am, Tuesday, 05'th Jan 2021
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommends th
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases
07:30am, Wednesday, 23'rd Dec 2020
SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in gen
Andreas Halvorsen's Top 5 Health Care Positions as of the 3rd Quarter
04:24pm, Thursday, 17'th Dec 2020
According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Ad
BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
08:30am, Monday, 07'th Dec 2020
Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise
Week In Review: CANbridge Closes $43 Million E Round For Rare Disease Drugs
03:04pm, Sunday, 06'th Dec 2020
CANbridge Pharma completed a $43 million Series E financing that is a follow-on to its $98 million Series D round, announced in February. Pfizer and Germany's BioNTech announced their partnered mRNA C
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Dec 2020
PALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on December 1,
Got $5,000 and 5 Years to Wait? Buy This Under-the-Radar Biotech Stock Now
06:27am, Thursday, 03'rd Dec 2020
This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.
• Application accepted under P riority R eview designation • Application accepted into Real Time Oncology Review (RTOR) pilot program • This is BridgeBio's s econd NDA a cceptance • �
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clinical tri
Week In Review: 3 $300 Million Deals For China Biopharma
02:03pm, Sunday, 08'th Nov 2020
China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy company, ra
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update
07:30am, Thursday, 05'th Nov 2020
-Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio's clinical and commercial development infrastructure to bear upon Eidos' Acoramidis
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 04'th Nov 2020
PALO ALTO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 1,
